tetano
Editor, Senior Moderator
Sci Rep
. 2024 Dec 28;14(1):31424.
doi: 10.1038/s41598-024-83026-x. Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021
Jia Ji[SUP] #[/SUP][SUP] 1 2 [/SUP], Lei Chen[SUP] #[/SUP][SUP] 3 [/SUP], Zhigang Wu[SUP] 1 [/SUP], Taoming Tang[SUP] 1 [/SUP], Linwei Zhu[SUP] 1 [/SUP], Miaojin Zhu[SUP] 1 [/SUP], Yan Chen[SUP] 4 [/SUP], Xiangyun Lu[SUP] 1 [/SUP], Hangping Yao[SUP] 5 6 [/SUP]
Affiliations
Influenza virus infections are a serious danger to people's health worldwide as they are responsible for seasonal flu outbreaks. There is an urgent need to improve the effectiveness and durability longevity of the immune response to influenza vaccines. We synthesized the CpG HP021 and examined the impact of it on the immune response to an influenza vaccine. In BALB/c mice, hemagglutination inhibition (HI) titers to the vaccine were increased four- to eightfold against H1N1, H3N2, BV, and BY viruses by 3 μg IIV4 + 40 μg CpG HP021 compared with those of the non-adjuvanted IIV4 group, and the CpG HP021 group had a broader HI activity. Additionally, the immune response was directed towards Type 1 T helper (Th1) cells due to the CpG HP021 adjuvant. The CpG HP021-adjuvanted IIV4 induced a higher number of T cells secreting interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), and increased the percentage of effector memory T cells in mice. In SD rats, the immune responses induced by IIV4 with CpG HP021 were similar to those in BALB/c mice. The development of CpG HP021 may expand the options for adjuvants in vaccines against infectious diseases.
Keywords: Antibody; CpG adjuvant; Hemagglutination inhibition; Quadrivalent influenza vaccine; T cell immunity.
. 2024 Dec 28;14(1):31424.
doi: 10.1038/s41598-024-83026-x. Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021
Jia Ji[SUP] #[/SUP][SUP] 1 2 [/SUP], Lei Chen[SUP] #[/SUP][SUP] 3 [/SUP], Zhigang Wu[SUP] 1 [/SUP], Taoming Tang[SUP] 1 [/SUP], Linwei Zhu[SUP] 1 [/SUP], Miaojin Zhu[SUP] 1 [/SUP], Yan Chen[SUP] 4 [/SUP], Xiangyun Lu[SUP] 1 [/SUP], Hangping Yao[SUP] 5 6 [/SUP]
Affiliations
- PMID: 39733119
- PMCID: PMC11682164
- DOI: 10.1038/s41598-024-83026-x
Influenza virus infections are a serious danger to people's health worldwide as they are responsible for seasonal flu outbreaks. There is an urgent need to improve the effectiveness and durability longevity of the immune response to influenza vaccines. We synthesized the CpG HP021 and examined the impact of it on the immune response to an influenza vaccine. In BALB/c mice, hemagglutination inhibition (HI) titers to the vaccine were increased four- to eightfold against H1N1, H3N2, BV, and BY viruses by 3 μg IIV4 + 40 μg CpG HP021 compared with those of the non-adjuvanted IIV4 group, and the CpG HP021 group had a broader HI activity. Additionally, the immune response was directed towards Type 1 T helper (Th1) cells due to the CpG HP021 adjuvant. The CpG HP021-adjuvanted IIV4 induced a higher number of T cells secreting interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), and increased the percentage of effector memory T cells in mice. In SD rats, the immune responses induced by IIV4 with CpG HP021 were similar to those in BALB/c mice. The development of CpG HP021 may expand the options for adjuvants in vaccines against infectious diseases.
Keywords: Antibody; CpG adjuvant; Hemagglutination inhibition; Quadrivalent influenza vaccine; T cell immunity.